Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic bone marrow-derived mesenchymal stromal cells for refractory ulcerative colitis proctitis
NL-OMON48876Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic bone marrow-derived mesenchymal stromal cells in autoimmune colitis, ulcerative proctitis, sponsored by Leiden University Medical Center. Started Aug 2018; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
autoimmune colitisulcerative proctitis
Beyond the preview
Go deeper on NL-OMON48876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48876.